Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.

Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA
Clin Cancer Res. 2011 17 (19): 6322-8

PMID: 21831955 · PMCID: PMC3186869 · DOI:10.1158/1078-0432.CCR-11-1080

MeSH Terms (16)

Adult Aged Aged, 80 and over Antineoplastic Agents Chemotherapy, Adjuvant Drug Resistance, Neoplasm ErbB Receptors Erlotinib Hydrochloride Gefitinib Humans Lung Neoplasms Middle Aged Mutation Protein Kinase Inhibitors Quinazolines Recurrence

Connections (1)

This publication is referenced by other Labnodes entities: